Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Heron Therapeutics, Inc.NASDAQ: HRTX

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 23.8% from a year ago

Common stock stood at $1.89M at the end of Q1 FY2026, up 23.8% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.

Context

  • Common stock amounted to 0.8% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +23.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.89M+0.2% QoQ
Last fiscal yearDec 2025
$1.88M+23.8% YoY
Year agoMar 2025
$1.52M+23.8% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.8%——
1 year+23.8%——
3-year CAGR+16.5%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
1.88M USD
Year-over-year change
+23.8%
4-year CAGR
+16.6%

Common Stock vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's Mar 2026 common stock of $1.89M is the 2nd highest of the 10 companies compared; the peer median is $20K.
  • Its year-over-year change of +23.8% is the 7th highest of 10, against a peer median of +30.5%.
  • Common stock amounts to 0.8% of total assets for HRTX, versus a peer median of 0.0%.
HRTX Competitors Peer median
Common Stock for HRTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$256.34M +119.4%+26.7%175.8%
HRTXHeron Therapeutics, Inc.Mar 2026$1.89M +23.8%+16.5%0.8%
PLXProtalix BioTherapeutics, Inc.Mar 2026$81K +3.8%+14.0%0.1%
TARAProtara Therapeutics, Inc.Mar 2026$55K +41.0%+70.0%0.0%
IVVDInvivyd, Inc.Mar 2026$28K +133.3%+36.5%0.0%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$20K +66.7%+95.7%0.0%
CHRSCoherus Oncology, Inc.Mar 2026$15K +25.0%+14.5%0.0%
OABIOmniAb, Inc.Mar 2026$14K +16.7%+5.3%0.0%
NTHINeonc Technologies Holdings, Inc.Mar 2026$2.48K +30.5%—0.1%
MDWDMediWound Ltd.Mar 2026$0 -100.0%+21.7%0.0%
Peer median (excluding HRTX) $20K+30.5%+24.2%0.0%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents90.54M15.36M28.68M25.8M28.65M
Short-term Investments67.04M69.49M51.73M33.48M17.98M
Net Receivables35.5M52.05M60.14M78.88M89.59M
Inventory48.38M54.57M42.11M53.16M92.75M
Other Current Assets013.96M6.12M17.69M9.1M
Total Current Assets254.42M205.44M188.77M209.01M238.07M
Property, Plant & Equipment (Net)33.56M29.81M25.6M17.65M12.4M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets17.72M15.71M8.13M6.48M5.41M
Total Non-current Assets51.28M45.52M33.73M24.13M17.81M
Total Assets305.71M250.95M222.51M233.15M255.88M
Account Payables3.87M3.59M3.8M11.71M8.99M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities13.48M11.28M7.85M7.96M8.61M
Total Current Liabilities71.06M82.36M79.69M91.46M96.1M
Long-term Debt149.08M149.28M173.75M174.73M140.64M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0241K241K615K4.81M
Total Non-current Liabilities157.08M155.02M176.79M175.34M145.45M
Total Liabilities228.14M237.38M256.48M266.8M241.54M
Common Stock1.02M1.19M1.5M1.52M1.88M
Retained Earnings(1.61B)(1.8B)(1.91B)(1.92B)(1.94B)
Accumulated OCI(6K)(19K)13K13K4K
Other Stockholders Equity00000
Minority Interest00000
Total Equity77.57M13.57M(33.97M)(33.65M)14.33M
Total Debt159.5M157.48M179.63M177.76M140.64M
Net Debt68.95M142.11M150.95M151.96M111.99M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.